Innovation in the
Field of Oncology

Millions of people today are living with cancer or have suffered from cancer. It is the second most common reason behind deaths in the United States. It has been predicted that approximately one-half of all men and one-third of all women in USA will develop cancer in their near future.

Inside The Company

Neiss Labs is in tune with the current manufacturing trends in healthcare industry. Our manufacturing plants are WHO-GMP compliant. The manufacturing facilities are in compliance with major regulatory bodies around the world including MCA, TGA and MCC.

Being in the business of healthcare products, Neiss Labs acknowledges quality as the first and the foremost important aspect. The key ingredients of manufacturing process clearly indicate the Neiss Labs’ commitment towards quality, they are…

  • Exhaustive Specifications for Inputs & Outputs
  • Validated Manufacturing Methods
  • Stringent In-process Controls
  • Validated Batch Manufacturing Procedures
  • Validated & Approved Analytical Procedures
  • Independent Quality Assurance Department
  • Elaborate Standard Operating Procedures

Our Products


  • Anastrazole
  • Aprepitant
  • Capecitabine
  • Erlotinib


  • Lenalidomide
  • Lomustin
  • Temozolomide

Global oncology Status as per 2014 Study

Global oncology spending reaches $100 billion in 2014
total global spending on oncology medicines

Including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, even as the share of total medicine spending of oncologics increased only modestly.

Growth in global spending on cancer drugs

Measured using ex-manufacturer prices and not reflecting off-invoice discounts, rebates or patient access programs – increased at a compound annual growth rate (CAGR) of 6.5 percent on a constant-dollar basis during the past five years.

Increasing value of Oncology products
By 2020,

Most oncology drugs will carry multiple indications reflecting developers’pursuit of genetic targets across multiple tumors, and the rise of immuno- oncologics,which may have more than six indications.

Of 88 cancer drugs marketed in 2014

40 were for single indications and 48 for multiple indications.

Oncology Manufacturer in India

As a manufacturer of medicines dedicated to treating cancer, we cover the entire gamut of medication including tablets, capsules, injections and ointments. These drugs are used in chemotherapy, immunotherapy, surgery or hormone therapy. Like other formulations, our cancer drugs are prepared under strict hygienic conditions. We maintain cleanliness of highest standards comparable to international levels. Some of the formulations processed in our works include Erlotinib, Imatinib, Capecitabine, Gefitinib and several oral anti-cancer tablets.

Treatment options of this disease include single or multiple therapies from amongst surgery, chemotherapy, radiation therapy, hormone therapy and immunotherapy. Except for radiation therapy, the other therapies are drug dependent and require superior quality formulations. Oncologic treatment varies from patient to patient, depending upon the exact location, extent of spread, stage of diagnosis and general health condition.

Manufacture of oncologic formulations are done keeping in mind the exact form of therapy needed. The formulations and their strengths vary accordingly. Each drug is carefully examined and tested keeping in compliance with leading drug manufacturing standards. We, at S.G. Biopharm, never compromise on quality as we believe that caring for cancer patients is of superior importance and overshadows any other prerogatives. We procure ingredients from authentic sources so as to maintain highest quality standards of our products. Several tests are conducted so as to ensure genuineness of our drugs and formulations.